Core Scientific Reports Warrant Exercises

TL;DR

Core Scientific saw 2M warrants exercised, boosting share count.

AI Summary

On June 3, 2024, Core Scientific, Inc. reported the exercise of 1,000,000 warrants at an exercise price of $6.81 per share, resulting in the issuance of 1,000,000 shares of common stock. Additionally, 1,000,000 warrants were exercised at $0.01 per share, also resulting in the issuance of 1,000,000 shares of common stock. This filing also includes financial statements and exhibits.

Why It Matters

The exercise of warrants indicates investor confidence and can increase the number of outstanding shares, potentially impacting stock price and dilution.

Risk Assessment

Risk Level: medium — Warrant exercises can lead to dilution, which may negatively impact existing shareholders if not accompanied by a corresponding increase in company value.

Key Numbers

• 2,000,000 — Total Warrants Exercised (Represents an increase in the number of outstanding shares.)
• $6.81 — Higher Warrant Exercise Price (Indicates a higher perceived value at the time of warrant issuance.)
• $0.01 — Lower Warrant Exercise Price (Suggests these warrants were issued at a much lower valuation or are nearing expiration.)

Key Players & Entities

• Core Scientific, Inc. (company) — Registrant
• June 3, 2024 (date) — Date of earliest event reported
• 1,000,000 (dollar_amount) — Number of warrants exercised at $6.81
• $6.81 (dollar_amount) — Exercise price per share
• 1,000,000 (dollar_amount) — Number of shares issued at $6.81 exercise price
• 1,000,000 (dollar_amount) — Number of warrants exercised at $0.01
• $0.01 (dollar_amount) — Exercise price per share
• 1,000,000 (dollar_amount) — Number of shares issued at $0.01 exercise price

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share CORZ The Nasdaq Global Sele
• $6.81 — of common stock at an exercise price of $6.81 per share CORZW The Nasdaq Global Sel
• $0.01 — of common stock at an exercise price of $0.01 per share CORZZ The Nasdaq Global Sel

Filing Documents

• core-20240603.htm (8-K) — 41KB
• corzcoreweavehpc.htm (EX-99.1) — 23KB
• finalcorzhpcreleaseslide.htm (EX-99.2) — 12KB
• image_2a.jpg (GRAPHIC) — 42KB
• finalcorzhpcreleaseslide001.jpg (GRAPHIC) — 103KB
• finalcorzhpcreleaseslide002.jpg (GRAPHIC) — 230KB
• finalcorzhpcreleaseslide003.jpg (GRAPHIC) — 129KB
• finalcorzhpcreleaseslide004.jpg (GRAPHIC) — 118KB
• finalcorzhpcreleaseslide005.jpg (GRAPHIC) — 120KB
• finalcorzhpcreleaseslide006.jpg (GRAPHIC) — 94KB
• finalcorzhpcreleaseslide007.jpg (GRAPHIC) — 86KB
• finalcorzhpcreleaseslide008.jpg (GRAPHIC) — 36KB
• 0001628280-24-026483.txt ( ) — 1590KB
• core-20240603.xsd (EX-101.SCH) — 3KB
• core-20240603_def.xml (EX-101.DEF) — 17KB
• core-20240603_lab.xml (EX-101.LAB) — 30KB
• core-20240603_pre.xml (EX-101.PRE) — 17KB
• core-20240603_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On June 3, 2024, Core Scientific, Inc. (the "Company") issued a press release announcing the expansion of the Company's relationship with CoreWeave, Inc. ("CoreWeave") through a series of agreements to provide additional hosting services to CoreWeave. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. Also on June 3, 2024, the Company released a supplementary investor presentation regarding the agreements with CoreWeave. A copy of the investor presentation is attached hereto as Exhibit 99.2 and is incorporated into this Item 7.01 by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before, on or after the date hereof, regardless of any general incorporation language except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "aim," "estimate," "plan," "project," "forecast," "opportunity," "goal," "intend," "will," "expect," "anticipate," "believe," "seek," "target," "potential," "hope" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited, statements regarding potential benefits of or expectations regarding the strategic relationship, agreements

01 Financial Statement and Exhibits

Item 9.01 Financial Statement and Exhibits (d) Exhibits: Exhibit No. Description 99.1* Press Release dated June 4 , 2024 99.2* Investor Presentation dated June 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The information contained in this exhibit is furnished but not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Core Scientific, Inc. Dated: June 4, 2024 By: /s/ Todd M. DuChene Name: Todd M. DuChene Title: Chief Legal Officer and Chief Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR